1). National Health Insurance Service (KR). Analysis of cancer patients in 2008 [Internet]. Seoul: National Health Insurance Service;2010. [cited 2010 Jun 5]. Available from:. http://www.nhis.or.kr/cms/board/board/Board.jsp?act=VIEW&communityKey=B0070&boardId=20108.
2). National Cancer Information Center (KR). Types of breast cancer [Internet]. Goyang: National Cancer Information Center;2013. [cited 2013 February 1]. Available from:. http://www.cancer.go.kr/mbs/cancer/jsp/cancer/cancer.jsp?cancerSeq=4757&menuSeq=4761&viewType=all&id=cancer_020112000000.
3). Korean Breast Cancer Society. Breast cancer facts & figures 2006–2008. Seoul: Korean Breast Cancer Society;2008.
4). Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst. 1981; 66(6):1191–1308.
Article
5). Wu C, Ray RM, Lin MG, Gao DL, Horner NK, Nelson ZC, Lampe JW, Hu YW, Shannon J, Stalsberg H, Li W, Fitzgibbons D, Porter P, Patterson RE, Satia JA, Thomas DB. A case-control study of risk factors for fibrocystic breast conditions: Shanghai Nutrition and Breast Disease Study, China, 1995–2000. Am J Epidemiol. 2004; 160(10):945–960.
Article
6). Magee PJ, McGlynn H, Rowland IR. Differential effects of isoflavones and lignans on invasiveness of MDA-MB-231 breast cancer cells in vitro. Cancer Lett. 2004; 208(1):35–41.
Article
7). Schley PD, Jijon HB, Robinson LE, Field CJ. Mechanisms of omega-3 fatty acid-induced growth inhibition in MDA-MB-231 human breast cancer cells. Breast Cancer Res Treat. 2005; 92(2):187–195.
Article
8). Klass CM, Shin DM. Current status and future perspectives of chemoprevention in head and neck cancer. Curr Cancer Drug Targets. 2007; 7(7):623–632.
Article
9). Lila MA. From beans to berries and beyond: teamwork between plant chemicals for protection of optimal human health. Ann N Y Acad Sci. 2007; 1114:372–380.
Article
10). Harborne JB. Comparative biochemistry of the flavonoids. New York (NY): Academic Press;1967.
11). Bae EA, Moon GS. A study on the antioxidative activities of Korean soybeans. J Korean Soc Food Sci Nutr. 1997; 26(2):203–208.
12). Ding M, Feng R, Wang SY, Bowman L, Lu Y, Qian Y, Castrano-va V, Jiang BH, Shi X. Cyanidin-3-glucoside, a natural product derived from blackberry, exhibits chemopreventive and chemotherapeutic activity. J Biol Chem. 2006; 281(25):17359–17368.
Article
13). Hou DX. Potential mechanisms of cancer chemoprevention by anthocyanins. Curr Mol Med. 2003; 3(2):149–159.
Article
14). Katsube N, Iwashita K, Tsushida T, Yamaki K, Kobori M. Induction of apoptosis in cancer cells by Bilberry (Vaccinium myrtil-lus) and the anthocyanins. J Agric Food Chem. 2003; 51(1):68–75.
Article
15). Yoon TH, Lee SW. Stability of anthocyanins in foods. Korean J Food Sci Technol. 1979; 11(1):63–73.
16). Kong JM, Chia LS, Goh NK, Chia TF, Brouillard R. Analysis and biological activities of anthocyanins. Phytochemistry. 2003; 64(5):923–933.
Article
17). Chu SK, Seo EY, Kim WK, Kang NE. Effect of cyanidin on cell motility and invasion in MDA-MB-231 human breast cancer cells. Korean J Nutr. 2008; 41(8):711–717.
18). Li L, Adams LS, Chen S, Killian C, Ahmed A, Seeram NP. Euge-nia jambolana Lam. Berry extract inhibits growth and induces apoptosis of human breast cancer but not non-tumorigenic breast cells. J Agric Food Chem. 2009; 57(3):826–831.
Article
19). Hui C, Bin Y, Xiaoping Y, Long Y, Chunye C, Mantian M, Wen-hua L. Anticancer activities of an anthocyanin-rich extract from black rice against breast cancer cells in vitro and in vivo. Nutr Cancer. 2010; 62(8):1128–1136.
Article
20). Weng MS, Ho CT, Ho YS, Lin JK. Theanaphthoquinone inhibits fatty acid synthase expression in EGF-stimulated human breast cancer cells via the regulation of EGFR/ErbB-2 signaling. Toxicol Appl Pharmacol. 2007; 218(2):107–118.
Article
21). Seo EY, Lee HS, Kim WK. Effect of [6]-gingerol on inhibition of cell proliferation in MDA-MB-231 human breast cancer cells. Korean J Nutr. 2005; 38(8):656–662.
22). Landesberg R, Cozin M, Cremers S, Woo V, Kousteni S, Sinha S, Garrett-Sinha L, Raghavan S. Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg. 2008; 66(5):839–847.
Article
23). Meiers S, Kemény M, Weyand U, Gastpar R, von Angerer E, Marko D. The anthocyanidins cyanidin and delphinidin are potent inhibitors of the epidermal growth-factor receptor. J Agric Food Chem. 2001; 49(2):958–962.
Article
24). Zhang Y, Vareed SK, Nair MG. Human tumor cell growth inhibition by nontoxic anthocyanidins, the pigments in fruits and vegetables. Life Sci. 2005; 76(13):1465–1472.
Article
25). Martin S, Andriambeloson E, Takeda K, Andriantsitohaina R. Red wine polyphenols increase calcium in bovine aortic endothelial cells: a basis to elucidate signalling pathways leading to nitric oxide production. Br J Pharmacol. 2002; 135(6):1579–1587.
Article
26). Koide T, Hashimoto Y, Kamei H, Kojima T, Hasegawa M, Terabe K. Antitumor effect of anthocyanin fractions extracted from red soybeans and red beans in vitro and in vivo. Cancer Biother Ra-diopharm. 1997; 12(4):277–280.
Article
27). Marko D, Puppel N, Tjaden Z, Jakobs S, Pahlke G. The substitution pattern of anthocyanidins affects different cellular signaling cascades regulating cell proliferation. Mol Nutr Food Res. 2004; 48(4):318–325.
Article
28). Sainsbury JR, Malcolm AJ, Appleton DR, Farndon JR, Harris AL. Presence of epidermal growth factor receptor as an indicator of poor prognosis in patients with breast cancer. J Clin Pathol. 1985; 38(11):1225–1228.
Article
29). Sainsbury JR, Farndon JR, Needham GK, Malcolm AJ, Harris AL. Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet. 1987; 1(8547):1398–1402.
30). Koenders PG, Beex LV, Geurts-Moespot A, Heuvel JJ, Kienhuis CB, Benraad TJ. Epidermal growth factor receptor-negative tumors are predominantly confined to the subgroup of estradiol receptor-positive human primary breast cancers. Cancer Res. 1991; 51(17):4544–4548.
31). Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177–182.
32). Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244(4905):707–712.
33). Toi M, Osaki A, Yamada H, Toge T. Epidermal growth factor receptor expression as a prognostic indicator in breast cancer. Eur J Cancer. 1991; 27(8):977–980.
Article
34). De Potter CR, Beghin C, Makar AP, Vandekerckhove D, Roels HJ. The neu-oncogene protein as a predictive factor for haematogenous metastases in breast cancer patients. Int J Cancer. 1990; 45(1):55–58.
35). Gusterson BA, Machin LG, Gullick WJ, Gibbs NM, Powles TJ, Elliott C, Ashley S, Monaghan P, Harrison S. c-erbB-2 expression in benign and malignant breast disease. Br J Cancer. 1988; 58(4):453–457.
Article
36). Sweeney C, Fambrough D, Huard C, Diamonti AJ, Lander ES, Cantley LC, Carraway KL 3rd. Growth factor-specific signaling pathway stimulation and gene expression mediated by ErbB receptors. J Biol Chem. 2001; 276(25):22685–22698.
Article
37). Crovello CS, Lai C, Cantley LC, Carraway KL 3rd. Differential signaling by the epidermal growth factor-like growth factors neu-regulin-1 and neuregulin-2. J Biol Chem. 1998; 273(41):26954–26961.
Article
38). Tzahar E, Pinkas-Kramarski R, Moyer JD, Klapper LN, Alroy I, Levkowitz G, Shelly M, Henis S, Eisenstein M, Ratzkin BJ, Sela M, Andrews GC, Yarden Y. Bivalence of EGF-like ligands drives the ErbB signaling network. EMBO J. 1997; 16(16):4938–4950.
Article
39). Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 1997; 16(7):1647–1655.
Article
40). Franke TF, Kaplan DR, Cantley LC. PI3K: downstream AKTion blocks apoptosis. Cell. 1997; 88(4):435–437.
Article
41). Meyskens FL Jr, Szabo E. Diet and cancer: the disconnect between epidemiology and randomized clinical trials. Cancer Epidemiol Biomarkers Prev. 2005; 14(6):1366–1369.
Article
42). Ramos S, Alía M, Bravo L, Goya L. Comparative effects of food-derived polyphenols on the viability and apoptosis of a human hepatoma cell line (HepG2). J Agric Food Chem. 2005; 53(4):1271–1280.
Article
43). Heo HJ, Lee CY. Strawberry and its anthocyanins reduce oxidative stress-induced apoptosis in PC12 cells. J Agric Food Chem. 2005; 53(6):1984–1989.
Article
44). Tessitore L, Davit A, Sarotto I, Caderni G. Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21 (CIP) expression. Carcinogenesis. 2000; 21(8):1619–1622.
45). Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest. 1999; 104(3):263–269.
Article
46). Afaq F, Syed DN, Malik A, Hadi N, Sarfaraz S, Kweon MH, Khan N, Zaid MA, Mukhtar H. Delphinidin, an anthocyanidin in pigmented fruits and vegetables, protects human HaCaT keratinocytes and mouse skin against UVB-mediated oxidative stress and apoptosis. J Invest Dermatol. 2007; 127(1):222–232.
Article
47). Lazzè MC, Savio M, Pizzala R, Cazzalini O, Perucca P, Scovassi AI, Stivala LA, Bianchi L. Anthocyanins induce cell cycle perturbations and apoptosis in different human cell lines. Carcinogenesis. 2004; 25(8):1427–1433.
Article
48). Shih PH, Yeh CT, Yen GC. Effects of anthocyanidin on the inhibition of proliferation and induction of apoptosis in human gastric adenocarcinoma cells. Food Chem Toxicol. 2005; 43(10):1557–1566.
Article